Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells

Journal of Cellular Physiology

Volumn 215, Issue 2, 2008, Pages 392-400

  Fediuc, S ^a   Pimenta, A S ^a   Gaidhu, M P ^a   Ceddia, R B ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN SENSITIZING AGENT; LIPID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; TROGLITAZONE; (6 (4 (2 PIPERIDIN 1 YLETHOXY)PHENYL)) 3 PYRIDIN 4 YLPYRAZOLO(1,5 A)PYRIMIDINE; (6-(4-(2-PIPERIDIN-1-YLETHOXY)PHENYL))-3-PYRIDIN-4-YLPYRAZOLO(1,5-A)PYRIMIDINE; ACETYL COENZYME A CARBOXYLASE; AMP ACTIVATED PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; CARNITINE PALMITOYLTRANSFERASE; CHROMAN DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA; LACTIC ACID; MULTIENZYME COMPLEX; PALMITIC ACID DERIVATIVE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRUVATE DEHYDROGENASE COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL VIABILITY; DECARBOXYLATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; MUSCLE CELL; MYOTUBE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; TISSUE DISTRIBUTION;

ACETYL-COA CARBOXYLASE; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE; CHROMANS; ENZYME ACTIVATION; FATTY ACIDS; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; LACTIC ACID; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PALMITATES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; PYRUVATE DEHYDROGENASE COMPLEX; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 40949102662     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21321     Document Type: Article

References (32)

1. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327.
2. Bonen A, Han XX, Habets DD, Febbraio M, Glatz JF, Luiken JJ. 2007. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICAR-stimulated fatty acid metabolism. Am J Physiol Endocrinol Metab 292:E1740-E1749.
3. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. 1999. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the zucker diabetic fatty rat. Diabetes 48:1415-1424.
4. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, Fürnsinn C. 2004. Thiazolidinediones, like metformin, inhibit respiratory complex 1: A common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059.
5. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. 1997. Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908.
6. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, Bonen A. 2004. A novel function for fatty acid translocase (FAT)/C D36: Involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 279:36235-36241.
7. Carling D. 2005. AMP-activated protein kinase: Balancing the scales. Biochimie 87:87-91.
8. Carling D, Hardie DG. 1989. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and Phosphorylase kinase. Biochim Biophys Acta 1012:81-86.
9. Castelein H, Gulick T, Declercq PE, Mannaerts GP, Moore DD, Baes MI. 1994. The peroxisome proliferator activated receptor regulates malic enzymegene expression. J Biol Chem 269:26754-26758.
10. Ceddia RB, Sweeney G. 2004. Creatine supplementation increases glucose oxidation and AMPK phosphorylation and reduces lactate production in L6 rat skeletal muscle cells. J Physiol 555:409-421.
11. Ceddia RB, William WN, Jr., Curi R. 1999. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: Evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord 23:75-82.
12. Curi R, Newsholme P, Newsholme EA. 1988. Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. Biochem J 250:383-388.
13. Fediuc S, Gaidhu MP, Ceddia RB. 2006a. Inhibition of insulin-stimulated glycogen synthesis by 5-aminoimidasole-4-carboxamide-1-beta-d-ribofuranoside- induced adenosine 5′-monophosphate-activated protein kinase activation: Interactions with akt, glycogen synthase kinase 3-3alpha/beta, and glycogen synthase in isolated rat soleus muscle. Endocrinology 147:5170-5177.
14. Fediuc S, Gaidhu MP, Ceddia RB. 2006b. Regulation of AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation by palmitate in skeletal muscle cells. J Lipid Res 47:412-420.
15. Fryer LG, Parbu-Patel A, Carling D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232.
16. Furnsinn C, Brunmair B, Neschen S, Roden M, Waldhausl W. 2000. Troglitazone directly inhibits CO(2) production from glucose and palmitate in isolated rat skeletal muscle. J Pharmacol Exp Ther 293:487-493.
17. Gaidhu MP, Fediuc S, Ceddia RB. 2006. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside-induced AMP-activated protein kinase phosphorylation inhibits basal and insulin-stimulated glucose uptake, lipid synthesis, and fatty acid oxidation in isolated rat adipocytes. J Biol Chem 281:25956-25964.
18. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128.
19. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. 1998. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872.
20. Konrad D, Rudich A, Bilan PJ, Patel N, Richardson C, Witters LA, Klip A. 2005. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48:954-966.
21. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH. 1989. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38:1089-1093.
22. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E. 2006. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291:E175-E181.
23. Lee MK, Olefsky JM. 1995. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44:1166-1169.
24. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. 1994. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43:1435-1439.
25. McGarry JD. 2002. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18.
26. Miles PD, Higo K, Romeo OM, Lee MK, Rafaat K, Olefsky JM. 1998. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes 47:395-400.
27. Nielsen JN, Wojtaszewski JF. 2004. Regulation of glycogen synthase activity and phosphorylation by exercise. Proc Nutr Soc 63:233-237.
28. Plosker GL, Faulds D. 1999. Troglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 57:409-438.
29. Randle PJ, Garland PB, Hales CN, Newsholme EA. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789.
30. Selby PL, Sherratt HS. 1989. Substituted 2-oxiranecarboxylic acids: A new group of candidate hypoglycaemic drugs. Trends Pharmacol Sci 10:495-500.
31. Spurway TD, Agius L, Stanley H, Sherratt A, Pogson CI. 1994. Measurement of carnitine palmitoyltransferase 1 in hepatocyte monolayers. Biochem Soc Trans 22:118S.
32. Sugden MC, Holness MJ. 1994. Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system. FASEB J 8:54-561.